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Kathryn B. Garber1,*Noninvasive Prenatal Screening in Low-Risk Women
The long-awaited results of a trial of noninvasive prenatal
testing in a general population of pregnant women might
serve as the death knell for maternal serum screening. The
blinded prospective trial included nearly 2,000 women
recruited from 21 centers across the United States. All
women included in the analysis received both standard
maternal serum screening (via a variety of approaches)
and noninvasive prenatal screening of cell-free fetal DNA
via the Verinata (Illumina) method. The primary goal of
the analysis was a comparison of false-positive rates
between the two screening approaches, and for trisomy
21, the results showed a more than 10-fold drop from
3.6% for maternal serum screening overall to 0.3% for
the method based on cell-free fetal DNA. On a cautionary
note, almost one-third of women were in their third
trimester when the sample for noninvasive prenatal
screening was drawn. This gestational age is later in preg-
nancy than prenatal screening would typically be per-
formed andwould be associated with a higher fetal fraction
in the cell-free DNA. However, excluding this portion of
the sample did not change the results significantly. The
analysis of cell-free fetal DNA is often called NIPT for
noninvasive prenatal testing, but it should be made clear
to women that this is a screen; although this study con-
firms that the positive predictive value of this approach is
much higher than it is for maternal serum screening, it is
still less than 50% for both trisomy 18 and trisomy 21,
meaning that confirmation of a positive result is needed
before decisions can be made about a pregnancy.
Bianchi et al. (2014). N. Engl. J. Med. 370, 799–808.
FMR1 Silenced by Its Own RNA
The expansion of a CGG repeat in the 50 UTR of FMR1 is
the mutation that leads to fragile X syndrome. Once the
repeat has 200 or more copies, the allele is silenced via
epigenetic modifications that include methylation of the
CpG island and the addition of repressive histone marks.
The mechanism linking repeat expansion and the epige-
netic modifications has been a mystery, particularly given
that transcriptional silencing of FMR1 is not recapitulated
in many experimental models. The discovery of human
embryonic stem cell lines that silence FMR1 when they
are induced to differentiate provided the tool necessary
for dissecting this process, revealing that when the CGG
repeat is long enough, a crucial step in gene silencing is1Department of Human Genetics, Emory University School of Medicine, Atlan
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RNA and the CGG repeat in the gene. Formation of this
hybrid can be blocked via knockdown of Fmr1 mRNA or
through treatment of cells with a small molecule that
binds the structural motif formed by G-G loops in the
mRNA, thereby keeping FMR1 transcriptionally active.
Colak et al. (2014). Science 343, 1002–1005.
Two New Candidate Genes Implicated in Infertility
Many times, when a couple has difficulty conceiving, the
underlying cause goes unexplained even with a clinical
work-up. Three recent papers based on exome sequencing
of individuals with Mendelian forms of nonsyndromic
infertility highlight two new candidate genes that might
explain fertility issues in one, or maybe even both, of the
sexes. Both geneproducts act on chromosomes. In two fam-
ilies affected by primary ovarian insufficiency, putative
pathogenic variation was found in HFM1, a gene whose
product is involved in homologous recombination. In
another family affected by primary ovarian insufficiency,
a homozygous frameshift variant was found in STAG3,
which encodes a cohesin subunit. So far, no men have
been identified to have two mutant alleles of STAG3, but
both male and female mice that lack STAG3 are infertile.
In this model, sister-chromatid cohesion is impaired and
gametogenesis is disrupted in both sexes with a meiotic
arrest at an early stage. Although double-strand breaks are
initiated, the repair of these breaks cannot be completed.
Because many other proteins work in the same processes
or complexes as STAG3 and HGM1, these studies also
suggest additional candidate genes for infertility.
Llano et al. (2014). Hum. Mol. Genet. Published online
March 7, 2014. http://dx.doi.org/10.1093/hmg/ddu051.
Caburet et al. (2014). N. Engl. J. Med. 370, 943–949.
Wang et al. (2014). N. Engl. J. Med. 370, 972–974.
Family History versus Personal Genome Testing
Recent work comparing personal genome test results with
family-history information gets at the heart of the crack-
down on these direct-to-consumer tests. For more than
750 people, Aiyar et al. compared risk categorization for
more than 20 conditions gleaned through genome scans
and through family-history interviews. What this com-
parison reveals is that people who are at high risk of
certain conditions on the basis of family history are not
uncommonly given an average or lower-than-average riskta, GA 30322, USA
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assessment for the same condition on the basis of personal
genome testing. As an example, only 5 of 14 womenwith a
family history suggestive of hereditary breast and ovarian
cancer syndrome received a lifetime breast cancer risk
assessment that was increased over that of the general pop-
ulation. Although the general public might think that
the two risk assessments are interchangeable or that the
high-tech approach provides more personalized risk infor-
mation, this analysis illustrates the discordance in risk
information gained via the two methods for a broad range
of conditions.
Aiyar et al. (2014). Genet. Med. 16, 231–237.
Don’t Blame It on the Population Boom
Many diseases with a genetic component—e.g., type 2 dia-
betes, obesity, and heart disease—have been on the rise.
The massive growth of the human population has gener-
ated an excess of rare genetic variation that went unno-
ticed before the advent of large-scale population sequence
data. Intuitively, it would seem that the population expan-484 The American Journal of Human Genetics 94, 483–484, April 3, 2sion could have shifted the burden of genetic disease as a
result, providing a potential explanation for the rise in
certain traits. Simons et al. modeled human history and
found that although some genetic variation might shift
around in frequency, if one looks at the mean number of
deleterious variants per individual, recent demographic
changes are predicted to have little impact. In other words,
we’re not more burdened with mutation today than we
were in the past. Supporting their models, a comparison
of real sequence data from African American and European
American populations documented a comparable muta-
tional burden in the groups despite different demographic
histories. Although it’s true that population growth can in-
crease the impact of a strongly deleterious allele, a concept
that is not new to population genetics, this analysis goes
on to show that excess rare variation should not contribute
substantially to the variance of complex traits. It looks like
we can’t blame the rise in common disease on the popula-
tion boom after all.
Simons et al. (2014). Nat. Genet. 46, 220–224.This Month in Our Sister JournalsCan BRCA1 Mutations Sometimes Be a Good Thing?
Mutations in BRCA1 or BRCA2 cause genetic instability,
ultimately leading to an increased risk of certain types of
cancer. A recent screen in C. elegans found that in certain
cases, loss of BRCA1 can instead promote genome stability.
Wolters et al. sought players in DNA repair through screens
forUVhypersensitivity inC. elegans. In smc-5, a gene encod-
ing a structuralmaintenance of chromosomesprotein, theypulled out two alleles causing genome instability and
increased sensitivity to replication stress. These effects can
be suppressed by mutation of the BRCA1 ortholog, brc-1,
leading to the thought that the persistence of BRCA1muta-
tions in humans might be because they can be advanta-
geous under certain conditions, such as replication stress.
Wolters et al. (2014). Genetics. Published online January 14,
2014. http://dx.doi.org/10.1534/genetics.113.158295.014
